20 results about "Cytosol" patented technology

Disclosed herein is a delivery agent that facilitates effective delivery of drugs and other compounds across lipid layers. The delivery agent disclosed herein provides lipid solubility under selected conditions and aqueous solubility under other conditions, and can effectively deliver compounds into the cell cytosol. The disclosed delivery agent also avoids deleterious interactions with serum and thus provide efficient in vivo delivery of therapeutic agents.

This invention aims to create a spatially isolated local reaction microenvironment for Rubisco by introducing a complete β-carboxysome microcompartment system. This design goal avoids oxygen inhibition, laying the foundation for ultimately achieving efficient and specific CO2 fixation. It provides a novel approach to overcome the fundamental problem of low efficiency of carbon-fixing enzymes in cytosols due to intense oxygen competition. By introducing the complete carboxysome system as a module, engineered yeast strains with high carboxylase activity and significantly improved ethanol production were obtained, providing a solid foundation for building next-generation yeast cell factories that produce high-yield ethanol using CO2 as a raw material.

This invention provides targeted conjugates and methods that improve the targeting and local in vivo delivery of oligonucleotides. [Solution] A composition containing a targeted oligonucleotide-HES conjugate is provided as a method for constructing and using the conjugate in therapeutic, diagnostic, and other applications. The oligonucleotide-HES complex contained in the targeted oligonucleotide-HES conjugate can cross membranes in a receptor-independent manner and can deliver oligonucleotides containing complementary sequences to the cytosol of living cells in vivo. The targeted oligonucleotide-HES conjugate has uses including the targeting and / or local delivery of antisense oligonucleotides, siRNAs, shRNAs, Dicer substrates, miRNAs, anti-miRNAs, and other nucleic acid sequences in living organisms.

This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.

The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).

The invention relates to a method for increasing plant growth by administering phytoinitiator mRNAs obtained from seedling chloroplasts. The mRNAs can either be translated directly into chloroplasts or first translated in the cytosol and subsequently imported into the chloroplasts as proteins. In both cases, the resulting proteins lead to the activation of hormonal signaling pathways, increased protein synthesis, and a significant increase in root biomass, shoot number, and hypocotyl growth. The invention further comprises formulations and application systems such as granules, sprays, or injections that enable efficient uptake and action of the mRNAs.

The application discloses a kind of lncRNA subcellular localization prediction method based on lightGBM, comprising, first, the nucleotide of the front section multiple of known lncRNA sequence is intercepted as sequence sample one;Then by based on single strand multiclass position-specific three nucleotide bias and reverse complementary kmer, sequence sample one is respectively characterized coding, the combination of two kinds of feature coding is vector;Use lightGMB as learning algorithm;Using 5-fold cross validation optimization reverse complementary kmer and LightGBM's hyperparameter;Most intercept unknown lncRNA sequence front end multiple bases as sequence sample two, and its single strand multiclass position-specific three nucleotide bias and the combination of optimized reverse complementary kmer feature coding is input in trained lightGBM, will obtain its localization subcellular type, the patent of the application can be according to long-chain non-coding RNA sequence prediction in cytoplasm, nucleus, ribosome, cytosol, exosome five subcellular positions, the application realizes simply, and prediction precision is high.

The invention relates to a method for increasing plant growth by delivering phyto-initiator mRNAs derived from chloroplasts of seedlings. The mRNAs may either be translated directly in chloroplasts or first translated in the cytosol and subsequently imported into the chloroplasts in the form of proteins. In both cases, the resulting proteins activate hormonal signalling pathways, increased protein synthesis, and bring about a significant enhancement of root biomass, shoot number and hypocotyl growth. The invention also relates to formulations and application systems such as granules, sprays or injections which enable efficient uptake and activity of the mRNAs.

The present disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.The identification of efficient enzymes capable of hydrolysing sucrose in its non-modified form, and which on its own enable the cell to utilize sucrose as a, or as the main and / or sole, carbon and / or energy source, i.e., without the need for multi-gene sucrose utilizing systems comprising several other heterologous polypeptides, such as other enzymes and / or transporters, is highly advantageous, since it allows for cost-effective use of sucrose in large scale production processes.

Compounds and methods are provided for facilitating delivery of an oligonucleotide, for example, into a nucleus and / or cytosol of a cell.

A method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in cytosol of a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the by-pass, selected from the genes encoding the enzymes pyruvate decarboxylase, acetaldehyde dehydrogenase, and acetylCoA synthetase; b) transforming said mutated yeast cell with an expression vector comprising a heterologous nucleotide sequence encoding a candidate polypeptide having potential enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA; c) testing said recombinant mutated yeast cell for its ability to grown on minimal medium containing glucose as sole carbon source, and d) identifying said candidate polypeptide as a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in the cytosol of said yeast cell when growth of said cell is observed.

The present invention provides methods for treating a neurodegenerative disease in a subject, preventing a neurodegenerative disease in a subject, increasing neurons in a region of the brain of a subject, increasing small ubiquitin-like modifier 1 (SUMO-1) in a region of the brain of a subject, reducing Sentrin-specific protease 1 (SENP-1) in a region of the brain of a subject, reducing Serine 129 phosphorylated alpha-synuclein in a region of the brain of a subject, reducing SENP-1 nuclear translocalization from the cytosol and / or reducing protein aggregates in a region of the brain of a subject. The method comprises administering to the subject an effective amount of a pharmaceutical composition comprising a specific SENP-1 inhibitor. The specific SENP-1 inhibitor may be selected from the group consisting of SUMO-2 aldehyde, momordin lc, streptonigrin, hinokiflavone, siRNA of SENP-1, and a combination thereof. Also provided is the pharmaceutical composition.

Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm infection in a human, an animal, or a plant are described. Compositions including isolated, native, bioactive crystals of CryH1 or CryH13 and inactivated or live recombinant bacteria expressing a CryH1 or CryH13 crystal proteins in the cytosol of the bacterium are described. Compositions suitable for pharmaceutical and agricultural applications are provided. Methods of administering a therapeutically effective amount of a composition to a human or animal suffering from a parasitic worm infection are provided. Compositions are provided for use as animal feed, feed supplement, or in waste treatment. Methods of agricultural applications for control of parasitic worm infections are provided.

The present invention relates to methods for the production of mRNA or the protein product encoded by a gene of interest in a eukaryotic host cell, wherein the transcription is effected in the cytosol. The present invention also relates to a method for the production of recombinant Modified vaccinia virus Ankara (MVA) vector or recombinant MVA virus and methods for producing pharmaceutical compositions comprising them.

This invention relates to effective and safe compositions comprising anionic gold-polydopamine core-shell nanoworms as alternative gene vectors to overcome endosome escape bottlenecks. The nanoworms can be used in methods for delivering therapeutic oligonucleotides to subjects. A polydopamine shell supports surface-adsorbed nucleic acids. Nanoworms encapsulating anionic nucleic acids can then enter cells without transfection agents and activate ClC3H in late endosomes. + / Cl ‑ Ion exchangers, to mediate H + and Cl ‑ Nanoworms accumulate within vesicles, leading to membrane rupture and ultimately escaping into the cytosol without cell-penetrating peptides or mechanical stimulation. Nanoworms can also be used for cell programming (i.e., primary macrophage polarization and stem cell differentiation) and for treating diseases (such as renal fibrosis and acute liver injury).

To provide a composition for promoting membrane fusion and use thereof.SOLUTION: In some aspects, fusosome compositions and methods are described herein, including membrane-encapsulated preparations comprising a fusogen. In some embodiments, the fusosome is capable of fusing with the target cell, thereby delivering the conjugated biological agent to the cytoplasm of the target cell. The present disclosure provides, in some aspects, a fusosome comprising (a) a lipid bilayer, (b) a lumen (e.g., comprising a cytosol) surrounded by the lipid bilayer, and (c) an exogenous or overexpressed fusogen, e.g., wherein the fusogen is disposed within the lipid bilayer, wherein the fusosome is derived from a source cell, and wherein the fusosome has partial or complete nuclear inactivation (e.g., removal of the nucleus).SELECTED DRAWING: Figure 1

The application belongs to the technical field of exosomes, and discloses a preparation method of artificial exosomes of blood cells of a crustacean Scylla paramamosain, which mainly comprises the following steps: 1) collecting blood cells of the Scylla paramamosain by centrifugation; 2) collecting cell membranes and cytoplasmic matrix respectively after blood cells are broken and centrifuged; and 3) obtaining artificial exosomes under certain reaction conditions. The exosomes obtained by the production method can be used as a carrier, and by carrying RNA or proteins, can be widely used in immunological research and disease prevention and treatment of the crustacean.

Disclosed herein are methods of delivering biomolecules to the cytosol of a cell using a substituted tertiary amine (STA) moiety.

Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a killed or inactivated recombinant bacterium expressing a crystal protein such as a Bacillus thuringiensis crystal protein (Cry) in the cytosol of the bacterium. The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A. The recombinant bacteria may be treated with an anti-microbial agent before or during administration to a subject.

Described in certain exemplary embodiments herein are engineered Anti-CRISPR (Acr) polypeptides and delivery systems engineered for delivery to the cytosol and / or nucleus of cells. In certain embodiments, an engineered Acr polypeptide comprises an Acr polypeptide operatively coupled to a cargo delivery molecule, wherein the cargo delivery molecule is capable of binding or otherwise interacting with a pore-forming polypeptide. Also described in certain exemplary embodiments are methods of Acr delivery to cells via the engineered Acr polypeptides and delivery systems of the present disclosure.